文献速递瓣膜外科心外重症与机械循环支持

经导管瓣膜置换治疗类癌心脏病:潜在范式的转变

Transcatheter Valve Replacement in Carcinoid Heart Disease: A Potential Change of Paradigm.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

本研究评估了经导管瓣膜置换在高手术风险类癌心脏病患者中的可行性与早期临床结局,纳入2021至2025年间9例患者的15次手术。结果显示单瓣、双瓣及三瓣置换均可行,中位随访9.9个月时所有患者临床改善,右心室直径减小,无感染性心内膜炎发生,提示完全经皮路径可行、安全且可能有益。

要点

  • 高手术风险类癌心脏病患者可行经导管单瓣、双瓣或三瓣置换。
  • 中位随访9.9个月所有患者临床改善,右心室直径减小。
  • 无感染性心内膜炎,1例短暂三尖瓣瓣周血栓无临床后果。

核心结论

  • 首组经导管瓣膜置换治疗类癌心脏病表明完全经皮路径可行、安全且可能有益。

研究设计与样本

  • 回顾性系列纳入2021至2025年间9例症状性类癌心脏病患者共15次手术。
  • 瓣膜受累包括肺动脉瓣9例、三尖瓣5例、主动脉瓣1例,瓣膜选择个体化。
  • 所有9例患者围术期接受静脉奥曲肽,结局包括手术成功、NYHA分级和超声评估。

主要发现

  • 4例单瓣置换(2例肺动脉瓣、2例三尖瓣),4例双瓣置换(肺动脉瓣和三尖瓣),1例三瓣置换(主动脉瓣、肺动脉瓣和三尖瓣)。
  • 1例高危患者三尖瓣手术后需中转,最终经延长住院后恢复。
  • 中位随访9.9个月(IQR 3.5)时所有患者临床改善,超声显示右心室直径减小。
  • 1例出现短暂三尖瓣瓣周血栓无功能障碍或临床后果,无感染性心内膜炎病例。
  • 1例术后4个月死于肿瘤进展。

临床怎么用

  • 对于高手术风险的类癌心脏病患者,经导管瓣膜置换可作为多瓣膜病变的个体化治疗选择。
  • 围术期静脉奥曲肽和根据解剖选择瓣膜(SAPIEN 3、TOPAZ、LUX)是方案组成部分。

局限性

  • 样本量小(9例患者15次手术),随访时间短(中位9.9个月)。
  • 早期结果需在更大队列和更长随访中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the feasibility and early clinical outcomes of transcatheter valve replacement in high-surgical-risk patients with carcinoid heart disease. MATERIALS AND METHODS: This study included 15 procedures performed in 9 patients with symptomatic carcinoid heart disease between 2021 and 2025. Valve involvement included the pulmonary valve in 9 cases, the tricuspid valve in 5 cases, and the aortic valve in 1 case. Valve selection (SAPIEN 3, TOPAZ, LUX) was individualized according to anatomical considerations. All 9 patients received intravenous periprocedural octreotide. Outcomes included procedural success, NYHA class, and echocardiographic evaluation of valve and ventricular function. RESULTS: Single-valve replacement was performed in 4 patients (2 pulmonary and 2 tricuspid). Double-valve replacement involving the pulmonary and tricuspid valves was performed in 4 patients, and 1 patient underwent triple-valve replacement (aortic, pulmonary, and tricuspid). One high-risk patient required conversion after a tricuspid procedure but ultimately recovered after a prolonged hospital stay. At a median follow-up of 9.9 months (IQR 3.5), all patients showed clinical improvement. One patient developed a transient tricuspid paravalvular thrombus without dysfunction or clinical consequence. Echocardiography demonstrated a reduction in right ventricular diameter. No case of endocarditis was observed. One patient died 4 months post-procedure from tumour progression. CONCLUSIONS: This first series of transcatheter valve replacements in carcinoid heart disease suggests that a complete percutaneous approach is feasible, safe, and potentially beneficial. These early results warrant confirmation in larger cohorts with longer follow-up and may represent a paradigm shift in the management of carcinoid valve disease.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Barbier MA, Gerard L, Grinberg D, et al. Transcatheter Valve Replacement in Carcinoid Heart Disease: A Potential Change of Paradigm. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41506885. doi:10.1093/icvts/ivag001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。